Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 2/20 | 0.32 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26618797 | 0.87 | PIK3CB (0.49) | PIK3CBPDPK1NOS3NOS1NOS2 | |
| SCHEMBL23346741 | 0.74 | PIK3CB (0.73) | PIK3CBPDPK1NOS3NOS1NOS2 | |
| SCHEMBL26607412 | 0.73 | PIK3CB (0.62) | PIK3CBPDPK1NOS3NOS1NOS2 | |
| SCHEMBL2298099 | 0.70 | PIK3CB (0.49) | PIK3CBPDPK1NOS3NOS1NOS2 | |
| SCHEMBL26596987 | 0.70 | PIK3CB (0.49) | PIK3CBPDPK1NOS3NOS1NOS2 | |
| SCHEMBL26633046 | 0.68 | MCHR1 (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL15741995 | 0.67 | CDK2 (0.46) | PIK3CBCDK2JAK2EGFRKDR | |
| SCHEMBL22153122 | 0.67 | JAK2 (0.40) | PIK3CBCDK2JAK2EGFRKDR | |
| SCHEMBL23478682 | 0.67 | FGFR1 (0.45) | PIK3CBPDPK1NOS3NOS1NOS2 | |
| SCHEMBL15741962 | 0.67 | JAK2 (0.40) | PIK3CBCDK2JAK2EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | Lakewood Amedex, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | CAT, MPO, NISCH | PIK3CB 1787/4885PDPK1 4054/4885NOS3 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.